 Ryan Porter
Concepts (210)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cartilage, Articular | 8 | 2025 | 47 | 2.180 |
Why?
| | Chondrogenesis | 4 | 2021 | 11 | 1.850 |
Why?
| | Chondrocytes | 8 | 2019 | 40 | 1.790 |
Why?
| | Avidin | 5 | 2022 | 8 | 1.750 |
Why?
| | Tissue Engineering | 5 | 2021 | 65 | 1.720 |
Why?
| | Osteogenesis | 8 | 2022 | 355 | 1.260 |
Why?
| | Drug Carriers | 4 | 2025 | 71 | 1.250 |
Why?
| | Cell Differentiation | 9 | 2020 | 643 | 0.860 |
Why?
| | Dexamethasone | 3 | 2017 | 431 | 0.730 |
Why?
| | Osteoporosis | 2 | 2020 | 156 | 0.710 |
Why?
| | Osteoarthritis | 2 | 2019 | 59 | 0.710 |
Why?
| | Interleukin-1beta | 3 | 2014 | 72 | 0.680 |
Why?
| | Joints | 1 | 2019 | 18 | 0.630 |
Why?
| | Bone and Bones | 3 | 2019 | 481 | 0.630 |
Why?
| | Sirtuins | 1 | 2019 | 10 | 0.620 |
Why?
| | Animals | 28 | 2025 | 13156 | 0.610 |
Why?
| | Forkhead Transcription Factors | 1 | 2019 | 109 | 0.590 |
Why?
| | Bone Morphogenetic Protein 2 | 6 | 2022 | 45 | 0.550 |
Why?
| | Injections, Intra-Articular | 6 | 2025 | 37 | 0.530 |
Why?
| | Anti-Inflammatory Agents | 1 | 2017 | 167 | 0.520 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2007 | 136 | 0.520 |
Why?
| | Anterior Cruciate Ligament | 2 | 2017 | 9 | 0.500 |
Why?
| | Cells, Cultured | 10 | 2019 | 1578 | 0.500 |
Why?
| | Rats | 12 | 2022 | 3302 | 0.490 |
Why?
| | Drug Delivery Systems | 2 | 2022 | 144 | 0.460 |
Why?
| | Cell Movement | 2 | 2014 | 245 | 0.440 |
Why?
| | Osteoblasts | 4 | 2019 | 463 | 0.430 |
Why?
| | Knee Joint | 1 | 2014 | 165 | 0.400 |
Why?
| | Bone Regeneration | 6 | 2022 | 74 | 0.390 |
Why?
| | NF-kappa B | 2 | 2014 | 313 | 0.380 |
Why?
| | Glycosaminoglycans | 3 | 2017 | 19 | 0.380 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2014 | 393 | 0.370 |
Why?
| | Horses | 3 | 2018 | 46 | 0.370 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 2 | 2022 | 14 | 0.370 |
Why?
| | Antigens, Differentiation | 1 | 2011 | 17 | 0.360 |
Why?
| | Rats, Inbred F344 | 5 | 2019 | 197 | 0.340 |
Why?
| | Rabbits | 4 | 2025 | 372 | 0.320 |
Why?
| | Peptides | 2 | 2025 | 220 | 0.310 |
Why?
| | Fracture Fixation, Intramedullary | 1 | 2009 | 10 | 0.310 |
Why?
| | Bone Marrow Cells | 2 | 2013 | 195 | 0.300 |
Why?
| | Muscle, Skeletal | 6 | 2017 | 786 | 0.300 |
Why?
| | Regenerative Medicine | 2 | 2022 | 10 | 0.300 |
Why?
| | Genetic Therapy | 5 | 2015 | 120 | 0.290 |
Why?
| | Alginates | 1 | 2007 | 9 | 0.280 |
Why?
| | Interleukin-1 | 1 | 2006 | 105 | 0.260 |
Why?
| | Cytokines | 3 | 2023 | 607 | 0.260 |
Why?
| | Static Electricity | 2 | 2017 | 21 | 0.260 |
Why?
| | Stem Cells | 2 | 2022 | 165 | 0.260 |
Why?
| | Protein Processing, Post-Translational | 1 | 2006 | 156 | 0.240 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2009 | 264 | 0.230 |
Why?
| | Osteoarthritis, Knee | 1 | 2025 | 98 | 0.220 |
Why?
| | Bone Transplantation | 2 | 2016 | 45 | 0.210 |
Why?
| | NAD | 1 | 2023 | 41 | 0.210 |
Why?
| | Stromal Cells | 1 | 2003 | 75 | 0.210 |
Why?
| | Fracture Healing | 2 | 2015 | 27 | 0.210 |
Why?
| | Cell Proliferation | 1 | 2007 | 986 | 0.210 |
Why?
| | Female | 11 | 2020 | 27181 | 0.200 |
Why?
| | Mesoderm | 1 | 2022 | 28 | 0.200 |
Why?
| | Regeneration | 1 | 2022 | 58 | 0.200 |
Why?
| | Gene Expression Regulation | 1 | 2006 | 952 | 0.190 |
Why?
| | Male | 16 | 2025 | 25991 | 0.190 |
Why?
| | Rats, Transgenic | 1 | 2021 | 20 | 0.190 |
Why?
| | Rats, Inbred Lew | 1 | 2021 | 49 | 0.190 |
Why?
| | Genes, Reporter | 2 | 2018 | 88 | 0.190 |
Why?
| | Energy Metabolism | 1 | 2023 | 286 | 0.180 |
Why?
| | Adipogenesis | 1 | 2020 | 49 | 0.170 |
Why?
| | Achilles Tendon | 2 | 2012 | 5 | 0.170 |
Why?
| | Cattle | 3 | 2019 | 207 | 0.170 |
Why?
| | Transforming Growth Factor beta1 | 2 | 2012 | 60 | 0.170 |
Why?
| | Humans | 19 | 2023 | 50673 | 0.170 |
Why?
| | Synovial Membrane | 1 | 2019 | 17 | 0.170 |
Why?
| | Interleukin-1alpha | 1 | 2019 | 10 | 0.160 |
Why?
| | Bone Diseases | 2 | 2011 | 96 | 0.160 |
Why?
| | Cartilage | 1 | 2019 | 47 | 0.160 |
Why?
| | Disease Models, Animal | 3 | 2025 | 1440 | 0.160 |
Why?
| | Wound Healing | 5 | 2017 | 186 | 0.150 |
Why?
| | Lentivirus | 1 | 2018 | 17 | 0.150 |
Why?
| | Aged | 6 | 2019 | 9770 | 0.150 |
Why?
| | Osteophyte | 1 | 2017 | 4 | 0.140 |
Why?
| | Drug Dosage Calculations | 1 | 2017 | 11 | 0.140 |
Why?
| | Permeability | 1 | 2017 | 66 | 0.140 |
Why?
| | Biological Transport | 1 | 2017 | 170 | 0.140 |
Why?
| | Autophagy | 1 | 2019 | 170 | 0.140 |
Why?
| | Models, Animal | 2 | 2015 | 226 | 0.130 |
Why?
| | Osteoclasts | 1 | 2019 | 427 | 0.120 |
Why?
| | Adenoviridae | 3 | 2012 | 47 | 0.120 |
Why?
| | Xanthenes | 1 | 2015 | 8 | 0.120 |
Why?
| | Genetic Vectors | 3 | 2015 | 128 | 0.120 |
Why?
| | Glucocorticoids | 2 | 2010 | 235 | 0.120 |
Why?
| | Ligaments | 1 | 2014 | 12 | 0.110 |
Why?
| | Half-Life | 1 | 2014 | 87 | 0.110 |
Why?
| | Tendons | 1 | 2014 | 27 | 0.110 |
Why?
| | Durapatite | 1 | 2013 | 24 | 0.110 |
Why?
| | Arthritis, Experimental | 1 | 2012 | 11 | 0.100 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2012 | 63 | 0.100 |
Why?
| | Sarcoma, Ewing | 1 | 2012 | 27 | 0.100 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2012 | 57 | 0.100 |
Why?
| | Cell Survival | 1 | 2014 | 588 | 0.100 |
Why?
| | Immune Tolerance | 1 | 2012 | 83 | 0.100 |
Why?
| | Tendon Injuries | 1 | 2012 | 15 | 0.100 |
Why?
| | DNA, Complementary | 2 | 2012 | 134 | 0.100 |
Why?
| | Cell Culture Techniques | 2 | 2014 | 97 | 0.090 |
Why?
| | Skull | 1 | 2011 | 77 | 0.090 |
Why?
| | Cell Adhesion | 1 | 2011 | 155 | 0.090 |
Why?
| | Orthopedic Procedures | 1 | 2011 | 71 | 0.090 |
Why?
| | Immunotherapy | 1 | 2012 | 236 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2019 | 1376 | 0.090 |
Why?
| | Fractures, Ununited | 1 | 2010 | 3 | 0.090 |
Why?
| | Polyethylene Glycols | 2 | 2022 | 86 | 0.090 |
Why?
| | Mice | 5 | 2023 | 5677 | 0.090 |
Why?
| | Tissue Transplantation | 1 | 2009 | 8 | 0.080 |
Why?
| | Cartilage Diseases | 1 | 2009 | 11 | 0.080 |
Why?
| | Gene Transfer Techniques | 1 | 2009 | 41 | 0.080 |
Why?
| | Integrin-Binding Sialoprotein | 2 | 2013 | 3 | 0.080 |
Why?
| | Collagen Type X | 1 | 2009 | 3 | 0.080 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2009 | 10 | 0.080 |
Why?
| | Therapeutic Irrigation | 1 | 2009 | 30 | 0.080 |
Why?
| | Transforming Growth Factor beta | 2 | 2022 | 134 | 0.080 |
Why?
| | Pressure | 1 | 2009 | 104 | 0.080 |
Why?
| | Adipose Tissue | 1 | 2009 | 192 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 3 | 2012 | 1589 | 0.070 |
Why?
| | Equipment Design | 1 | 2009 | 290 | 0.070 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2008 | 56 | 0.070 |
Why?
| | Transduction, Genetic | 3 | 2014 | 45 | 0.070 |
Why?
| | Hexuronic Acids | 1 | 2007 | 5 | 0.070 |
Why?
| | Glucuronic Acid | 1 | 2007 | 8 | 0.070 |
Why?
| | RNA, Messenger | 2 | 2017 | 1089 | 0.070 |
Why?
| | Gene Expression | 3 | 2017 | 610 | 0.070 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2006 | 10 | 0.070 |
Why?
| | Insulin-Like Growth Factor Binding Protein 2 | 1 | 2006 | 10 | 0.070 |
Why?
| | Culture Media, Conditioned | 1 | 2006 | 47 | 0.070 |
Why?
| | Receptor, IGF Type 1 | 1 | 2006 | 21 | 0.070 |
Why?
| | Biocompatible Materials | 1 | 2007 | 66 | 0.070 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2006 | 28 | 0.070 |
Why?
| | Signal Transduction | 2 | 2012 | 1618 | 0.060 |
Why?
| | Transcription, Genetic | 1 | 2006 | 362 | 0.060 |
Why?
| | Synovial Fluid | 1 | 2025 | 18 | 0.060 |
Why?
| | Knee Injuries | 1 | 2025 | 29 | 0.060 |
Why?
| | Sialoglycoproteins | 1 | 2003 | 10 | 0.050 |
Why?
| | Lipoprotein Lipase | 1 | 2003 | 13 | 0.050 |
Why?
| | Cell Size | 1 | 2003 | 46 | 0.050 |
Why?
| | Osteocalcin | 1 | 2003 | 43 | 0.050 |
Why?
| | Models, Biological | 1 | 2006 | 721 | 0.050 |
Why?
| | Biotechnology | 1 | 2022 | 13 | 0.050 |
Why?
| | Extracellular Matrix | 1 | 2003 | 109 | 0.050 |
Why?
| | Femur | 2 | 2016 | 130 | 0.050 |
Why?
| | Mice, Inbred BALB C | 2 | 2014 | 294 | 0.050 |
Why?
| | Tissue Distribution | 1 | 2022 | 167 | 0.050 |
Why?
| | Collagen | 1 | 2003 | 204 | 0.050 |
Why?
| | Oxidation-Reduction | 1 | 2023 | 315 | 0.050 |
Why?
| | Homeostasis | 1 | 2023 | 204 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2016 | 3244 | 0.050 |
Why?
| | Recombinant Proteins | 1 | 2022 | 479 | 0.050 |
Why?
| | Mice, Knockout | 1 | 2023 | 842 | 0.040 |
Why?
| | Transgenes | 2 | 2011 | 50 | 0.040 |
Why?
| | Metabolism | 1 | 2019 | 25 | 0.040 |
Why?
| | Coculture Techniques | 1 | 2019 | 142 | 0.040 |
Why?
| | Collagen Type II | 1 | 2018 | 5 | 0.040 |
Why?
| | Cell Aggregation | 1 | 2018 | 6 | 0.040 |
Why?
| | Implants, Experimental | 1 | 2018 | 6 | 0.040 |
Why?
| | Hydrogen | 1 | 2018 | 13 | 0.040 |
Why?
| | Fluorescence | 1 | 2018 | 41 | 0.040 |
Why?
| | Luciferases | 1 | 2018 | 48 | 0.040 |
Why?
| | Hyaluronic Acid | 1 | 2018 | 33 | 0.040 |
Why?
| | Transplantation, Autologous | 2 | 2010 | 481 | 0.040 |
Why?
| | X-Ray Microtomography | 1 | 2017 | 80 | 0.040 |
Why?
| | Adult | 4 | 2016 | 13636 | 0.030 |
Why?
| | Age Factors | 1 | 2020 | 1120 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 2017 | 155 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 463 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2016 | 144 | 0.030 |
Why?
| | Animals, Genetically Modified | 1 | 2015 | 47 | 0.030 |
Why?
| | Sheep | 1 | 2015 | 87 | 0.030 |
Why?
| | Biopsy | 1 | 2017 | 589 | 0.030 |
Why?
| | Random Allocation | 1 | 2016 | 289 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2017 | 958 | 0.030 |
Why?
| | Curcumin | 1 | 2014 | 18 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2014 | 160 | 0.030 |
Why?
| | Middle Aged | 3 | 2016 | 12648 | 0.030 |
Why?
| | Diphosphates | 1 | 2013 | 6 | 0.030 |
Why?
| | Pyrophosphatases | 1 | 2013 | 12 | 0.030 |
Why?
| | Spectroscopy, Fourier Transform Infrared | 1 | 2013 | 19 | 0.030 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2013 | 73 | 0.030 |
Why?
| | Phosphoric Diester Hydrolases | 1 | 2013 | 32 | 0.030 |
Why?
| | Alkaline Phosphatase | 1 | 2013 | 94 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2013 | 156 | 0.030 |
Why?
| | HLA-A2 Antigen | 1 | 2012 | 11 | 0.030 |
Why?
| | Mice, Inbred DBA | 1 | 2012 | 45 | 0.020 |
Why?
| | Collagen Type III | 1 | 2012 | 6 | 0.020 |
Why?
| | Rupture | 1 | 2012 | 24 | 0.020 |
Why?
| | Blotting, Western | 1 | 2013 | 577 | 0.020 |
Why?
| | Species Specificity | 1 | 2012 | 187 | 0.020 |
Why?
| | Phosphorylation | 1 | 2013 | 526 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2012 | 119 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 212 | 0.020 |
Why?
| | Stress, Mechanical | 1 | 2012 | 92 | 0.020 |
Why?
| | Calcium | 1 | 2013 | 399 | 0.020 |
Why?
| | Collagen Type I | 1 | 2012 | 81 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2012 | 540 | 0.020 |
Why?
| | Phenotype | 1 | 2013 | 739 | 0.020 |
Why?
| | Cell Lineage | 1 | 2009 | 83 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2010 | 5294 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2009 | 135 | 0.020 |
Why?
| | Graft Survival | 1 | 2009 | 160 | 0.020 |
Why?
| | Radiography | 1 | 2010 | 486 | 0.020 |
Why?
| | Growth Differentiation Factors | 1 | 2008 | 2 | 0.020 |
Why?
| | Time | 1 | 2008 | 28 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2012 | 833 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 1403 | 0.020 |
Why?
| | Cell Line | 1 | 2009 | 1001 | 0.020 |
Why?
|
|
Porter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|